BMY

Gregory Scott Meyers

Known title: EVP, Chief Digital & Tech Off.CIK: 0001908769

Associated companies

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

October 17, 2026

Bristol Myers Squibb sees mixed trial results and dividend focus. Recent articles note BMY's 4.2% dividend yield and the trade‑off investors face between income and growth. Analysts also point to momentum in the stock rally but question whether new drugs can sustain further upside, especially after mixed Phase 3 results for its pulmonary fibrosis treatment. A shift in the company's portfolio toward newer products is also highlighted, adding context to the current market view.

this person other insiders at BMY

Transaction History

BMY▲ Buy$0
BMY▼ Sell$0
BMY▼ Sell$64K
BMY▲ Buy$0
BMY▼ Sell$0
BMY▼ Sell$75K
BMY▲ Buy$0
BMY▼ Sell$0
BMY▼ Sell$257K
BMY▲ Buy$0
BMY▼ Sell$46K
BMY▲ Buy$0
BMY▼ Sell$123K
BMY▲ Buy$0
BMY▼ Sell$63K
BMY▼ Sell$73K
BMY▲ Buy$0
BMY▼ Sell$288K
BMY▼ Sell$0
BMY▼ Sell$0
BMY▲ Buy$0
BMY▼ Sell$0
BMY▲ Buy$0
BMY▼ Sell$49K
BMY▲ Buy$0
BMY▼ Sell$37K
BMY▲ Buy$0
BMY▼ Sell$0
BMY▼ Sell$82K
BMY▲ Buy$0
BMY▼ Sell$52K

We use analytics to understand how market-wall is used. No personal data is sold.